 |
MaaT Pharma
Last updated: April 19, 2024
Herve Affagard - CEO and Cofounder
Country: France | Funding: €31.9M (+)
Website: http://maatpharma.com/
MaaT Pharma (Microbiota as a Therapy) is intended to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis.
Website: http://maatpharma.com/
MaaT Pharma (Microbiota as a Therapy) is intended to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis.
